The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways

Journal of Pathology

Volumn 208, Issue 5, 2006, Pages 724-732

  Masuya, D ^a   Huang, C ^a   Liu, D ^a   Nakashima, T ^a   Yokomise, H ^a   Ueno, M ^a   Nakashima, N ^b   Sumitomo, S ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Bax; HAUSP; Lung cancer; mdm2; p21; p53

Indexed keywords

HERPESVIRUS ASSOCIATED UBIQUITIN SPECIFIC PROTEASE; PROTEIN BAX; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE TARGETING; GENETIC STABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENDOPEPTIDASES; FOLLOW-UP STUDIES; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645240086     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1931     Document Type: Article

References (35)

1. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-4063.
2. Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Kinoshita M, et al. Mutation of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int J Oncol 1998;12:553-563.
3. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
4. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
5. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-299.
6. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 1995;23:2584-2592.
7. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003;15:164-171.
8. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003;13:49-58.
9. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-27.
10. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002;416:648-653.
11. Komiya T, Hosono Y, Hirashima T, Masuda N, Yasumitsu T, Nakagawa K, et al. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 1997;3:1831-1835.
12. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002;20:3865-3871.
13. Huang CL, Kohno N, Inufusa H, Kodama K, Taki T, Miyake M. Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53. Am J Pathol 1999;155:955-965.
14. Sekido Y, Sato M, Usami N, Shigemitsu K, Mori S, Maeda O, et al. Establishment of a large cell lung cancer cell line (Y-ML-1B) producing granulocyte colony-stimulating factor. Cancer Genet Cytogenet 2002;137:33-42.
15. WAF1/CIP1 in pancreatic cancer. Br J Cancer 1997;76:299-305.
16. Ando T, Shibata H, Suzuki T, Kurihara I, Hayashi K, Hayashi M, et al. The possible role of apoptosis-suppressing genes, bcl-2 and mcl-1/EAT in human adrenal tumors. Endocr Res 1998;24:955-960.
17. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986;46:4244s-4248s.
18. Higashiyama M, Doi O, Kodama K, Yokouchi H, Kasugai T, Ishiguro S, et al. Mdm2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 1997;75:1302-1308.
19. Ko JL, Cheng YW, Cheng SL, Su JM, Chen CY, Lee H. Mdm2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer. Int J Cancer 2000;89:265-270.
20. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998;17:7151-7160.
21. Hershko A, Ciechanover A, Varshavsky A. The ubiquitin system. Nature Med 2000;6:1073-1081.
22. Papa FR, Hochstrasser M. The yeast DOA4 gene encodes a deubiquitinating enzyme related to a product of the human tre-2 oncogene. Nature 1993;366:313-319.
23. Moazed D, Johnson AD. A deubiquitinating enzyme interacts with SIR4 and regulates silencing in S. cerevisiae. Cell 1996;86:667-677.
24. Zhu Y, Carroll M, Papa RF, Hochstrasser M, D'Andrea AD. DUB-1, a deubiquitinating enzyme with growth suppressing activity. Proc Natl Acad Sci U S A 1996;93:3275-3279.
25. Everett RD, Meredith M, Orr A, Cross A, Kathoria M, Parkinson J. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J 1997;16:1519-1530.
26. Holowaty MN, Sheng Y, Nguyen T, Arrowsmith C, Frappier L. Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP. J Biol Chem 2003;278:47753-47761.
27. Hu M, Li P, Li M, Li W, Yao T, Wu JW, et al. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 2002;111:1041-1054.
28. Mori S, Ito G, Usami N, Yoshioka H, Ueda Y, Kodama Y, et al. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer 2004;100:1673-1682.
29. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Williams NN, et al. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer. Cancer Res 2003;63:3352-3355.
30. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-704.
31. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
32. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 1996;271:12695-12698.
33. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
34. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
35. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:763-771.